Product Information
LATISSE 0.03% EYELASH SOLUTION is a brand product labeled by Allergan, Inc., priced at $40.9950 per ML under NDC 00023361670. Its NADAC has been published 410 times since Jul 18, 2018.
FDA first approved this application on Dec 24, 2008. Its Orange Book therapeutic-equivalence code is AT.
The High Outlier badge above means this manufacturer's average price in the bimatoprost market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
.3 mg/mL
Manufacturer
Allergan, Inc.NDC
00023361670
Classification
Brand
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC
Effective Date
8/19/2026
Active Ingredients
BIMATOPROSTApproval Type
New Drug (NDA)
FDA Application
NDA022369FDA Approved
12/24/2008
TE Code
AT
On Market Since
1/26/2009
Pharmacological Classes
Price Statistics
The NADAC for LATISSE 0.03% EYELASH SOLUTION has been published 410 times since Jul 18, 2018, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $40.9950 per ML |
|---|---|
| All-time high | $41.5038 (Jan 12, 2022) |
| All-time low | $40.8717 (Mar 18, 2020) |
| 52-week high | $41.1181 |
| 52-week low | $40.9050 |
| Median price | $41.0711 |
| Average price | $41.1709 |
| Largest weekly change | +1.5% (Jan 20, 2021) |
| Weeks tracked | 410 |
| Tracking since | Jul 18, 2018 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 47% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of LATISSE 0.03% EYELASH SOLUTION?
The current National Average Drug Acquisition Cost (NADAC) for LATISSE 0.03% EYELASH SOLUTION, manufactured by Allergan, Inc., is $40.9950 per ML (NDC 00023361670), effective Aug 19, 2026.
How has the price of LATISSE 0.03% EYELASH SOLUTION changed over time?
Over the history we have for it, the NADAC for LATISSE 0.03% EYELASH SOLUTION has held within roughly two percent of its current level. It has been tracked across 410 weekly CMS publications since Jul 18, 2018.
What are the highest and lowest recorded NADAC prices for LATISSE 0.03% EYELASH SOLUTION?
Since Jul 18, 2018, the NADAC for LATISSE 0.03% EYELASH SOLUTION has ranged from a low of $40.8717 (Mar 18, 2020) to a high of $41.5038 (Jan 12, 2022), with a median of $41.0711 per ML.
Are there cheaper alternatives to LATISSE 0.03% EYELASH SOLUTION?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BIMATOPROST 0.03% EYELASH SOLN, is $21.5809 per ML — about 47% below LATISSE 0.03% EYELASH SOLUTION.
Who manufactures LATISSE 0.03% EYELASH SOLUTION?
LATISSE 0.03% EYELASH SOLUTION (NDC 00023361670) is labeled by Allergan, Inc., and CMS classifies it as a brand product.